MRVIMaravai LifeSciences Holdings, Inc.
$7.47+177% 1Y
$7.47
$2.6952 weeks$8.99
The financials
Maravai LifeSciences Holdings, Inc. by the numbers
Maravai LifeSciences Holdings, Inc. (MRVI) reported revenue of $51M in Q2 2026 (quarter ended Jun 30, 2026), up 8.5% from the same quarter a year earlier. That came with a gross margin of 40% and net loss of $12M. For the full year FY2025, revenue was $186M (−28% year on year) and net income −$131M. Its largest region in Q2 2026 was United States at $31M, 47% of the disclosed total, ahead of North America at 38%. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $51M | $47M | +8.5% |
| Gross profit | $21M | $7.8M | +166% |
| Operating income | −$15M | −$66M | n/a |
| Net income | −$12M | −$40M | n/a |
| Diluted EPS | −$0.08 | −$0.27 | n/a |
| Geographic | Revenue | Share |
|---|---|---|
| United States | $31M | 47% |
| North America | $25M | 38% |
| EMEA | $6.1M | 9.3% |
| Asia Pacific | $3.7M | 5.6% |
| Latin And Central America | $193K | 0.3% |
Business segments
Revenue split by geographic segment, from SEC XBRL filings.
Latest period: Jun 2026Total $65.6M (-21%)
Latin And Central America grew +133% year on yearUnited States +2.0% year on year
Segment Latestquarter on quarteryear on year
- United States$30.9M$30.9Mquarter on quarter -12%year on year +2.0%-12%+2.0%
- North America$24.6M$24.6Mquarter on quarter -12%year on year +3.2%-12%+3.2%
- EMEA$6.1M$6.1Mquarter on quarter -65%year on year +49%-65%+49%
- Asia Pacific$3.7M$3.7Mquarter on quarter +94%year on year +22%+94%+22%
- Latin And Central America$193.0K$193.0Kquarter on quarter +133%year on year +133%+133%+133%